- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07649577
Generative AI for Medication Counselling and Adherence in Community Pharmacies
Human-AI Collaboration in the Pharmacy: A Cluster Randomized Controlled Trial of Generative AI for Medication Counselling and Adherence
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Amman, Jordânia
- Petra University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Patient Eligibility Criteria
Inclusion Criteria:
Adults aged 18 years or older. Presenting with a new prescription or a refill for a chronic medication requiring counseling within one of the following classes: antihypertensives, oral antidiabetics, lipid-lowering agents, anticoagulants, or inhaled maintenance therapies.
Willing and able to provide informed consent.
Exclusion Criteria:
Presence of acute infections. Diagnosis of psychiatric disorders or oncological conditions. Presence of severe acute illness requiring urgent medical referral. Cognitive impairment precluding informed consent. Hearing or communication barriers that prevent interview completion without the presence of a caregiver.
Inability to provide a follow-up phone number for the 30-day adherence assessment.
Pharmacy and Pharmacist (Cluster) Eligibility Criteria
Inclusion Criteria:
Pharmacies legally registered in Jordan, providing routine prescription dispensing services, having at least one licensed pharmacist available during recruitment hours, and agreeing to participate for the full trial period.
Licensed pharmacists with a minimum of 2 years of clinical experience, working in participating pharmacies, providing direct patient counseling, and consenting to take part in the study.
Exclusion Criteria:
Pharmacies that are already using structured AI-assisted counseling tools as part of their routine practice.
Pharmacists on temporary placement for less than one month. Pharmacists not involved in patient-facing counseling.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Intervention arm procedures
For all eligible patients in the intervention arm, the pharmacist performed the standard patient assessment and determined which medicine(s) needed counselling.
Then, the pharmacist input a prompt in a de-identified format into ChatGPT®.
The prompt was a request for an easy-to-understand counselling document with information regarding the indications for the medication, dosage, schedule, route, course, missed doses, possible side effects, important precautions, storage, and advice on taking the medicine as prescribed (Appendix A).
The pharmacist ensured that the content generated by the AI was accurate and clear, making corrections where necessary, and then gave verbal counselling to the patient.
|
For all eligible patients in the intervention arm, the pharmacist performed the standard patient assessment and determined which medicine(s) needed counselling. Then, the pharmacist input a prompt in a de-identified format into ChatGPT®. The prompt was a request for an easy-to-understand counselling document with information regarding the indications for the medication, dosage, schedule, route, course, missed doses, possible side effects, important precautions, storage, and advice on taking the medicine as prescribed (Appendix A). The pharmacist ensured that the content generated by the AI was accurate and clear, making corrections where necessary, and then gave verbal counselling to the patient. The AI output was never provided to the patients without pharmacist evaluation. It is worth noting that pharmacists could also reject the AI output as inaccurate, insufficient, hazardous, and inappropriate altogether. Reproducibility was ensured through documenting the date and time, prompt te
Outros nomes:
|
|
Sem intervenção: Control arm procedures
Pharmacies randomized to the control arm continued to provide usual medication counselling according to their standard routine practice, without access to the AI prompt templates or study AI workflow.
Control pharmacists used their usual professional references, as would occur in routine care, but they were not trained in or asked to use ChatGPT® during the trial period.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of Applicable Counseling Domains Provided Correctly
Prazo: day 0
|
Defined as the proportion of clinically applicable counseling domains communicated accurately during the encounter, compared with a medication-specific reference sheet.
Scored on a 0-100 scale, calculated as (Number of applicable domains correctly informed / Total number of applicable domains) x 100.Correctness score= (Number of applicable domains
|
day 0
|
|
Percentage of Essential Counseling Domains Addressed
Prazo: Day 0
|
Defined as the proportion of essential counseling domains that were addressed during the encounter.
Scored on a 0-100 scale, calculated as (Number of applicable domains addressed / Total number of applicable domains) x 100.
|
Day 0
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Counseling Deficiencies Categorized by Clinical Severity
Prazo: Day 0
|
The frequency of omitted or incorrect counseling information, independently assessed by a panel of pharmacists using a 3-point scale: Low Severity (minor wording issues), Moderate Severity (errors leading to sub-therapeutic effects), and High Severity (errors with high potential for significant patient harm).
|
Day 0
|
|
Score on the General Medication Adherence Scale (GMAS)
Prazo: 30 Days Post-Encounter
|
Medication adherence assessed via telephone follow-up using the continuous total score from the General Medication Adherence Scale (GMAS).
Higher scores indicate better medication adherence.
|
30 Days Post-Encounter
|
|
Number of Participants Achieving Good Adherence
Prazo: 30 Days Post-Encounter
|
The number of participants meeting the validated threshold for "good adherence" based on their GMAS survey responses.
|
30 Days Post-Encounter
|
|
Total Score on the Immediate Patient Understanding (Teach-Back) Assessment
Prazo: Day 0
|
A brief interviewer-administered understanding assessment based on teach-back principles.
Scores range from 0 to 4, with higher scores indicating a better understanding of the medication.
|
Day 0
|
|
Total Score on the Patient Satisfaction Questionnaire
Prazo: Day 0
|
A questionnaire covering clarity, usefulness, confidence, and overall satisfaction.
Total scores range from 5 to 25, with higher scores indicating greater patient satisfaction.
|
Day 0
|
|
Time Spent on Face-to-Face Counseling
Prazo: Day 0
|
Total face-to-face counseling time measured in minutes using audio timestamps from the start of counseling to completion.
|
Day 0
|
|
Number of Encounters Based on AI Output Acceptance Level
Prazo: Day 0
|
The proportion of encounters in which the AI-generated counseling output was fully accepted, edited before delivery, or rejected outright by the pharmacist.
|
Day 0
|
|
Number of AI-Related Discrepancies Identified
Prazo: Day 0
|
The frequency of detected AI inaccuracies prior to counseling, such as omitted counseling points, overly technical wording, or incomplete missed-dose advice.
|
Day 0
|
|
Number of Clinical Near Misses and Safety Incidents
Prazo: Day 0
|
The number of encounters featuring a "near miss" (an AI error identified and corrected by the pharmacist before reaching the patient) or an "incident" (inaccurate information that actually reached the patient).
|
Day 0
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Abdel-Qader, D. H., Al Meslamani, A. Z., Lewis, P. J., & Hamadi, S. (2021). Incidence, nature, severity, and causes of dispensing errors in community pharmacies in Jordan. International journal of clinical pharmacy, 43(1), 165-173. https://doi.org/10.1007/s11096-020-01126-w Abdel-Qader, D. H., et al. (2024). A comprehensive analysis of public satisfaction: Community pharmacists' pandemic preparedness in Jordan. Journal of Applied Pharmaceutical Science, 14(8), 160-168. Abdel-Qader, D. H., et al. (2025). Drug-Drug interaction management among pharmacists in Jordan: A national comparative survey. Pharmacy, 137. https://doi.org/10.3390/pharmacy13050137 Abu Hammour, K., et al. (2023). ChatGPT in pharmacy practice: A cross-sectional exploration of Jordanian pharmacists' perception, practice, and concerns. Journal of Pharmaceutical Policy and Practice, 16(1), 115. Ali, S., Shimels, T., & Bilal, A. I. (2019). Assessment of patient counseling on dispensing of medicines in outpatient pharmacy of Tikur-Anbessa Specialized Hospital, Ethiopia. Ethiopian journal of health sciences, 29(6), 727. Campbell, M. K., et al. (2012). Consort 2010 statement: Extension to cluster randomised trials. BMJ, 345. Chan, A.-W., et al. (2015). SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Revista Panamericana de Salud Pública, 38, 506-514. Elayeh, E. R., et al. (2019). Use of secret simulated patient followed by workshop based education to assess and improve inhaler counseling in community pharmacy in Jordan. Pharmacy Practice (Granada), 17(4). Fattah, F. H., et al. (2025). Comparative analysis of ChatGPT and Gemini (Bard) in medical inquiry: A scoping review. Frontiers in digital health, 7, 1482712. FIP, I. P. F. (2021). Medication review and medicines use review: A toolkit for pharmacists Colophon. FIP, I. P. F. (2025). An artificial intelligence toolkit for pharmacy: An introduction and resource guide for pharmacists. (March). Hammad, E. A., et al. (2022). Feasibi
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do Sistema Endócrino
- Doenças Vasculares
- Processos Patológicos
- Atributos da doença
- Doenças Metabólicas
- Doenças do sistema imunológico
- Doenças Respiratórias
- Doenças pulmonares
- Distúrbios do Metabolismo da Glicose
- Doenças brônquicas
- Doenças Pulmonares Obstrutivas
- Hipersensibilidade Respiratória
- Hipersensibilidade, Imediata
- Hipersensibilidade
- Distúrbios do metabolismo lipídico
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Doença Pulmonar Obstrutiva Crônica
- Hipertensão
- Asma
- Doenças cardiovasculares
- Diabetes Mellitus
- Dislipidemias
- Doença crônica
Outros números de identificação do estudo
- Petrauniversity
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doenças cardiovasculares
-
Mayo ClinicConcluídoRisco Cardiovascular | Prevenção CardiovascularEstados Unidos
-
Alliance For Medical Research in AfricaInstitut Pasteur de DakarAtivo, não recrutandoCâncer | Mortalidade | Cardiovascular | Doença cardiovascularSenegal
-
Martha BiddleInscrevendo-se por conviteRisco Cardiovascular | Redução do Risco CardiovascularEstados Unidos
-
Fu Jen Catholic UniversityRecrutamentoDoença cardiovascular | Cirurgia CardiovascularTaiwan
-
University of DelawareAtivo, não recrutandoFator de Risco Cardiovascular | Saúde cardiovascularEstados Unidos
-
IRCCS Policlinico S. DonatoIRCCS San Raffaele; Fondazione Policlinico Universitario Agostino Gemelli IRCCS e outros colaboradoresRecrutamentoRisco Cardiovascular | Risco cardiovascular genéticoItália
-
Weill Medical College of Cornell UniversityAmerican Heart AssociationRecrutamentoCardiovascular | Saúde cardiovascular | Risco Cardiovascular (CV) | Fatores de risco para doenças cardiovasculares (DCV)Estados Unidos
-
Oregon Health and Science UniversityConcluídoDoença cardiovascular | Fatores de Risco CardiovascularEstados Unidos
-
Medical College of WisconsinNational Center for Complementary and Integrative Health (NCCIH)ConcluídoDoenças cardiovasculares | Fator de Risco Cardiovascular | Saúde cardiovascularEstados Unidos
-
Hospital Mutua de TerrassaConcluídoDoença cardiovascular | Fator de Risco CardiovascularEspanha